IBDEI2S5 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46667,1,4,0)
 ;;=4^D86.0
 ;;^UTILITY(U,$J,358.3,46667,2)
 ;;=^5002442
 ;;^UTILITY(U,$J,358.3,46668,0)
 ;;=D86.2^^206^2305^49
 ;;^UTILITY(U,$J,358.3,46668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46668,1,3,0)
 ;;=3^Sarcoidosis of Lung w/ Sarcoidosis of Lymph Nodes
 ;;^UTILITY(U,$J,358.3,46668,1,4,0)
 ;;=4^D86.2
 ;;^UTILITY(U,$J,358.3,46668,2)
 ;;=^5002444
 ;;^UTILITY(U,$J,358.3,46669,0)
 ;;=D86.1^^206^2305^50
 ;;^UTILITY(U,$J,358.3,46669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46669,1,3,0)
 ;;=3^Sarcoidosis of Lymph Nodes
 ;;^UTILITY(U,$J,358.3,46669,1,4,0)
 ;;=4^D86.1
 ;;^UTILITY(U,$J,358.3,46669,2)
 ;;=^5002443
 ;;^UTILITY(U,$J,358.3,46670,0)
 ;;=D86.89^^206^2305^51
 ;;^UTILITY(U,$J,358.3,46670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46670,1,3,0)
 ;;=3^Sarcoidosis of Oth Sites
 ;;^UTILITY(U,$J,358.3,46670,1,4,0)
 ;;=4^D86.89
 ;;^UTILITY(U,$J,358.3,46670,2)
 ;;=^5002453
 ;;^UTILITY(U,$J,358.3,46671,0)
 ;;=D86.3^^206^2305^52
 ;;^UTILITY(U,$J,358.3,46671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46671,1,3,0)
 ;;=3^Sarcoidosis of Skin
 ;;^UTILITY(U,$J,358.3,46671,1,4,0)
 ;;=4^D86.3
 ;;^UTILITY(U,$J,358.3,46671,2)
 ;;=^5002445
 ;;^UTILITY(U,$J,358.3,46672,0)
 ;;=D86.9^^206^2305^53
 ;;^UTILITY(U,$J,358.3,46672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46672,1,3,0)
 ;;=3^Sarcoidosis,Unspec
 ;;^UTILITY(U,$J,358.3,46672,1,4,0)
 ;;=4^D86.9
 ;;^UTILITY(U,$J,358.3,46672,2)
 ;;=^5002454
 ;;^UTILITY(U,$J,358.3,46673,0)
 ;;=M35.01^^206^2305^54
 ;;^UTILITY(U,$J,358.3,46673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46673,1,3,0)
 ;;=3^Sicca Syndrome w/ Keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,46673,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,46673,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,46674,0)
 ;;=M35.02^^206^2305^55
 ;;^UTILITY(U,$J,358.3,46674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46674,1,3,0)
 ;;=3^Sicca Syndrome w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,46674,1,4,0)
 ;;=4^M35.02
 ;;^UTILITY(U,$J,358.3,46674,2)
 ;;=^5011788
 ;;^UTILITY(U,$J,358.3,46675,0)
 ;;=M35.03^^206^2305^56
 ;;^UTILITY(U,$J,358.3,46675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46675,1,3,0)
 ;;=3^Sicca Syndrome w/ Myopathy
 ;;^UTILITY(U,$J,358.3,46675,1,4,0)
 ;;=4^M35.03
 ;;^UTILITY(U,$J,358.3,46675,2)
 ;;=^5011789
 ;;^UTILITY(U,$J,358.3,46676,0)
 ;;=M35.09^^206^2305^57
 ;;^UTILITY(U,$J,358.3,46676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46676,1,3,0)
 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
 ;;^UTILITY(U,$J,358.3,46676,1,4,0)
 ;;=4^M35.09
 ;;^UTILITY(U,$J,358.3,46676,2)
 ;;=^5011791
 ;;^UTILITY(U,$J,358.3,46677,0)
 ;;=M35.04^^206^2305^58
 ;;^UTILITY(U,$J,358.3,46677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46677,1,3,0)
 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
 ;;^UTILITY(U,$J,358.3,46677,1,4,0)
 ;;=4^M35.04
 ;;^UTILITY(U,$J,358.3,46677,2)
 ;;=^5011790
 ;;^UTILITY(U,$J,358.3,46678,0)
 ;;=M35.00^^206^2305^59
 ;;^UTILITY(U,$J,358.3,46678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46678,1,3,0)
 ;;=3^Sicca Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,46678,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,46678,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,46679,0)
 ;;=M32.10^^206^2305^62
 ;;^UTILITY(U,$J,358.3,46679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46679,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
 ;;^UTILITY(U,$J,358.3,46679,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,46679,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,46680,0)
 ;;=M32.9^^206^2305^61
 ;;^UTILITY(U,$J,358.3,46680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46680,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
